Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons
暂无分享,去创建一个
A. Lupatov | A. Gisina | Konstantin N. Yarygin | Y-A Kim | Konstantin N Yarygin | Alexey Lupatov | K. Yarygin
[1] M. Kucińska,et al. Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets , 2023, International journal of molecular sciences.
[2] Y. Miyagi,et al. Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer , 2023, AntiCancer Research.
[3] K. Yamashita,et al. Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer , 2023, PloS one.
[4] A. Nakagawara,et al. Molecular Regulation of Autophagy and Asymmetric Cell Division by Cancer Stem Cell Marker CD133 , 2023, Cells.
[5] K. Yarygin,et al. Telomeres and Telomerase in the Control of Stem Cells , 2022, Biomedicines.
[6] A. Kopylov,et al. TRIM28 Is a Novel Regulator of CD133 Expression Associated with Cancer Stem Cell Phenotype , 2022, International journal of molecular sciences.
[7] Niannian Liu,et al. CEACAM5 targeted by miR-498 promotes cell proliferation, migration and epithelial to mesenchymal transition in gastric cancer , 2022, Translational oncology.
[8] J. Duyster,et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. , 2022, Cancer letters.
[9] Cuiping Yang,et al. Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation , 2022, Cell Death & Differentiation.
[10] R. Pei,et al. Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer. , 2022, Journal of materials chemistry. B.
[11] Reena Philip,et al. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jian Wu,et al. Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma , 2021, Molecular medicine reports.
[13] V. M. P. Pereira,et al. Cancerous and non-neoplastic stem cells in the stomach similarly express CD44 and CD133. , 2021, Acta histochemica.
[14] Parul Gupta,et al. Expression of CD44 and CD133 stem cell markers in squamous cell carcinoma of esophagus , 2021, Indian journal of pathology & microbiology.
[15] V. Zgoda,et al. CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells. , 2021, Cancer biomarkers : section A of Disease markers.
[16] K. N. Yarygin,et al. Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs , 2021, Bulletin of Experimental Biology and Medicine.
[17] M. Waligóra,et al. CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion , 2021, Journal of clinical medicine.
[18] H. Salih,et al. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia , 2021, Cancers.
[19] T. Ozaki,et al. CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt‐mediated protein synthesis and inhibition of apoptosis , 2021, FEBS open bio.
[20] T. Tongtawee,et al. Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer. , 2021, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[21] Y. Xuan,et al. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy , 2021, Cancer Immunology, Immunotherapy.
[22] S. Weissman,et al. Colorectal Cancer Stem Cell States Uncovered by Simultaneous Single‐Cell Analysis of Transcriptome and Telomeres , 2021, Advanced science.
[23] J. Bartek,et al. Expression of the stem cell marker CD133 in malignant meningioma. , 2020, Clinical neuropathology.
[24] B. Baradaran,et al. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[25] Mohamed Hassan,et al. Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways , 2020, Oncogene.
[26] Zhen-Bin Ma,et al. Characterisation of a subpopulation of CD133+ cancer stem cells from Chinese patients with oral squamous cell carcinoma , 2020, Scientific Reports.
[27] J. Moffat,et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. , 2020, Cell stem cell.
[28] Zhe Zhang,et al. Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells , 2020, BMC Cancer.
[29] Xuewen Li,et al. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions. , 2020, Cancer biomarkers : section A of Disease markers.
[30] D. Ribatti,et al. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview , 2020, Translational oncology.
[31] Hamid Cheshomi,et al. Prognostic and Clinical Value of CD44 and CD133 in Esophageal Cancer: A Systematic Review and Meta-analysis. , 2020, Iranian journal of allergy, asthma, and immunology.
[32] S. Antović,et al. High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer. , 2020, Polski przeglad chirurgiczny.
[33] Yijun Kang,et al. The prognostic role of CD133 expression in patients with osteosarcoma , 2020, Clinical and Experimental Medicine.
[34] H. Abdollahi,et al. Cancer stem cells: A review from origin to therapeutic implications , 2020, Journal of cellular physiology.
[35] K. Majidzadeh-A,et al. Enrichment of cancer stem‐like cells by the induction of epithelial‐mesenchymal transition using lentiviral vector carrying E‐cadherin shRNA in HT29 cell line , 2019, Journal of cellular physiology.
[36] P. Nelson,et al. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer , 2019, Clinical Cancer Research.
[37] Junsoo Park,et al. CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition , 2019, PloS one.
[38] H. Clevers,et al. Defining Adult Stem Cell Function at Its Simplest: The Ability to Replace Lost Cells through Mitosis. , 2019, Cell stem cell.
[39] K. Yarygin,et al. Proliferative Activity of Colorectal Cancer Cells with Different Levels of CD133 Expression , 2019, Bulletin of Experimental Biology and Medicine.
[40] G. Pearson,et al. Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis , 2019, Journal of clinical medicine.
[41] W. Liu,et al. CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression. , 2019, Biochemical and biophysical research communications.
[42] M. Arafa,et al. Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma , 2019, Pathologica.
[43] A. Nakagawara,et al. Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region , 2019, Scientific Reports.
[44] I. Ellis,et al. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer , 2018, Breast Cancer Research and Treatment.
[45] B. Rueda,et al. PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells , 2018, Molecular Cancer Research.
[46] J. Chiang,et al. Surface Molecular Markers of Cancer Stem Cells: Computation Analysis of Full-Text Scientific Articles , 2018, Bulletin of Experimental Biology and Medicine.
[47] Prabhaker Mishra,et al. Prognostic Value of Cancer Stem Cell Markers in Potentially Malignant Disorders of Oral Mucosa: A Meta-analysis , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[48] Jian-Hui Huang,et al. Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis , 2018, Journal of cancer research and therapeutics.
[49] A. LeBeau,et al. The identification of a novel antibody for CD133 using human antibody phage display , 2018, The Prostate.
[50] Kyung-Hee Kim,et al. Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma , 2018, AntiCancer Research.
[51] P. Meltzer,et al. Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells , 2018, Molecular Cancer Therapeutics.
[52] Junrong Wu,et al. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients , 2018, Medicine.
[53] Zhiqiang Wu,et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial , 2018, Oncoimmunology.
[54] Yifeng Tao,et al. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies , 2018, Cellular Physiology and Biochemistry.
[55] S. Dooley,et al. CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma , 2018, Journal of Translational Medicine.
[56] C. Shang,et al. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells , 2018, Cancer biology & therapy.
[57] S. Ishihara,et al. CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis , 2018, International journal of oncology.
[58] D. Corbeil,et al. Prominin‐1/CD133: Lipid Raft Association, Detergent Resistance, and Immunodetection , 2017, Stem cells translational medicine.
[59] Do Hyung Kim,et al. Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview , 2017, Journal of clinical medicine.
[60] Shugang Li,et al. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis. , 2017, Future oncology.
[61] M. Abolhasani,et al. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma. , 2017, Experimental and molecular pathology.
[62] H. Harada,et al. Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry , 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[63] B. Lloveras,et al. Prognostic impact of CD133 expression in Endometrial Cancer Patients , 2017, Scientific Reports.
[64] Wei-Chieh Huang,et al. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients , 2017, BMC Cancer.
[65] K. N. Yarygin,et al. Cancer stem cell molecular markers verified in vivo , 2017, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.
[66] H. Kim,et al. Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133 , 2017, Scientific Reports.
[67] S. Mayor,et al. The mystery of membrane organization: composition, regulation and roles of lipid rafts , 2017, Nature Reviews Molecular Cell Biology.
[68] N. Shen,et al. Expression of CD133, E-cadherin and WWOX in colorectal cancer and related analysis , 2017, Pakistan journal of medical sciences.
[69] Juan Wang,et al. Prognostic Value of Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma: a Meta-analysis , 2017, Scientific Reports.
[70] Dexi Chen,et al. CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma , 2017, Scientific Reports.
[71] Menglin Wu,et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer , 2016, Medicine.
[72] Bo Cheng,et al. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis , 2016, Oncotarget.
[73] Zhangfa Song,et al. The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis , 2016, Oncotarget.
[74] Donghwi Kim,et al. Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines , 2016, Clinical & Experimental Metastasis.
[75] Hui Yang,et al. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma , 2016, Molecular Neurobiology.
[76] Xin-hua Liang,et al. CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation , 2016, Oncotarget.
[77] M. Moradi-Lakeh,et al. Expression of CD133 Cancer Stem Cell Marker in Melanoma: A Systematic Review and Meta-Analysis , 2016, The International journal of biological markers.
[78] Chen Li,et al. CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation , 2016, Oncotarget.
[79] Jiang Li,et al. CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis , 2016, Oncotarget.
[80] D. Geller,et al. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells , 2015, Oncotarget.
[81] S. Nam,et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53 , 2015, Cell Death and Disease.
[82] Yiming Li,et al. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: A systematic review and meta-analysis , 2015, Oncotarget.
[83] Leizhen Zheng,et al. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. , 2015, International journal of clinical and experimental pathology.
[84] K. Nan,et al. Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma , 2015, Medicine.
[85] B. Guo,et al. [Expressions of CD133, E-cadherin, and Snail in epithelial ovarian cancer and their clinicopathologic and prognostic implications]. , 2015, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[86] L. Pardo,et al. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells , 2015, PloS one.
[87] C. Liang,et al. An aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype , 2015, Oncogenesis.
[88] Haibin Xia,et al. Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody. , 2015, Oncology letters.
[89] A. Hampl,et al. Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines , 2015, International journal of molecular medicine.
[90] M. Ge,et al. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis , 2015, Journal of experimental & clinical cancer research : CR.
[91] Y. Liu,et al. Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth , 2015, Oncotarget.
[92] C. Zhong,et al. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis , 2015, Tumor Biology.
[93] Zhiqing Liang,et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition , 2015, Oncotarget.
[94] Jian Feng,et al. High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer , 2015, Disease markers.
[95] A. Hjelmeland,et al. Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells , 2014, PloS one.
[96] S. Millar,et al. CD133 expression correlates with membrane beta-catenin and e-cadherin loss from human hair follicle placodes during morphogenesis , 2014, The Journal of investigative dermatology.
[97] Yan Zhou,et al. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis , 2014, Tumor Biology.
[98] X. Bian,et al. Is CD133 Expression a Prognostic Biomarker of Non-Small-Cell Lung Cancer? A Systematic Review and Meta-Analysis , 2014, PloS one.
[99] W. Huttner,et al. Human Prominin-1 (CD133) Is Detected in Both Neoplastic and Non-Neoplastic Salivary Gland Diseases and Released into Saliva in a Ubiquitinated Form , 2014, PloS one.
[100] J. Moffat,et al. Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. , 2014, Journal of molecular biology.
[101] L. Goodell,et al. Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133+ Tumor-Initiating Cells , 2014, PloS one.
[102] S. Takao,et al. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis , 2014, Molecular Cancer.
[103] R. Luo,et al. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. , 2013, International journal of clinical and experimental pathology.
[104] Jiayin Yang,et al. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis , 2013, European journal of gastroenterology & hepatology.
[105] M. Rinaldo,et al. Nuclear Localization of Cancer Stem Cell Marker CD133 in Triple-Negative Breast Cancer: A Case Report , 2013, Tumori.
[106] Xiang Du,et al. CD133: a cancer stem cells marker, is used in colorectal cancers. , 2013, World journal of gastroenterology.
[107] N. Normanno,et al. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction , 2013, Cell Death and Disease.
[108] Y. Liu,et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells , 2013, Proceedings of the National Academy of Sciences.
[109] S. Chang,et al. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy , 2013, BMC Cancer.
[110] L. Donovan,et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. , 2013, International journal of oncology.
[111] Hongyang Wang,et al. CD133/Prominin-1-Mediated Autophagy and Glucose Uptake Beneficial for Hepatoma Cell Survival , 2013, PloS one.
[112] Shicai Chen,et al. CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.
[113] D. Corbeil,et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges , 2013, The Journal of pathology.
[114] P. Álvarez,et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy , 2012, Journal of Translational Medicine.
[115] Jian Huang,et al. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis , 2012, BMC Cancer.
[116] A. Gingras,et al. Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. , 2012, Cell reports.
[117] N. Potter,et al. A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles. , 2012, Translational oncology.
[118] D. Hwang,et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. , 2012, Cancer letters.
[119] S. Mocellin,et al. Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis , 2012, Annals of Surgical Oncology.
[120] A. Unterberg,et al. Expression and regulation of AC133 and CD133 in glioblastoma , 2011, Glia.
[121] S. Natsugoe,et al. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial–mesenchymal transition in pancreatic cancer , 2011, Human Cell.
[122] Hyung-Seok Kim,et al. The presence of stem cell marker‐expressing cells is not prognostically significant in glioblastomas , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.
[123] D. Corbeil,et al. CD133 and membrane microdomains: old facets for future hypotheses. , 2011, World Journal of Gastroenterology.
[124] H. Ueno,et al. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. , 2011, International journal of oncology.
[125] J. Moffat,et al. CD133 Protein N-Glycosylation Processing Contributes to Cell Surface Recognition of the Primitive Cell Marker AC133 Epitope* , 2011, The Journal of Biological Chemistry.
[126] Yi-Wei Chen,et al. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells , 2011, Cancer.
[127] R. Qin,et al. CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. , 2011, World journal of gastroenterology.
[128] D. Lingwood,et al. Cholesterol modulates glycolipid conformation and receptor activity. , 2011, Nature chemical biology.
[129] B. Kristensen,et al. Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[130] S. Kyo,et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. , 2010, Human pathology.
[131] C. Forster,et al. Identification of a novel monoclonal antibody recognizing CD133. , 2010, Journal of immunological methods.
[132] C. Eberhart,et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.
[133] L. del Vecchio,et al. The percentage of CD133+ cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection , 2010, BMC Cancer.
[134] Robert E. Brown,et al. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. , 2010, Annals of clinical and laboratory science.
[135] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[136] G. Stassi,et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. , 2010, Cancer research.
[137] D. Roberts,et al. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.
[138] L. Mariani,et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.
[139] J. Fantini,et al. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. , 2009, Cancer letters.
[140] I. Bisson,et al. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.
[141] Austin G Smith,et al. CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent , 2009, PloS one.
[142] S. Rafii,et al. SURROGATE MARKERS PREDICT ANGIOGENIC POTENTIAL AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME , 2009, Neurosurgery.
[143] K. Camphausen,et al. Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro , 2009, Molecular Cancer Research.
[144] Nicolò Riggi,et al. Identification of cancer stem cells in Ewing's sarcoma. , 2009, Cancer research.
[145] C. Cavaliere,et al. Correction: Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours , 2008, PLoS ONE.
[146] L. Ricci-Vitiani,et al. Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.
[147] D. Benos,et al. CD133 Is a Marker of Bioenergetic Stress in Human Glioma , 2008, PloS one.
[148] C. Cavaliere,et al. Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours , 2008, PloS one.
[149] W. Huttner,et al. The Stem Cell Marker CD133 (Prominin-1) Is Expressed in Various Human Glandular Epithelia , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[150] B. Kristensen,et al. CD133 identifies perivascular niches in grade II–IV astrocytomas , 2008, Journal of Neuro-Oncology.
[151] D. Gisselsson,et al. Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.
[152] M. Biffoni,et al. Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.
[153] A. Molven,et al. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas , 2008, BMC Cancer.
[154] D. Wion,et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. , 2007, Cancer letters.
[155] W. Huttner,et al. Focus on molecules: prominin-1 (CD133). , 2007, Experimental eye research.
[156] C. Heeschen,et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.
[157] Hua Zhao,et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence , 2007, Cancer.
[158] D. Corbeil,et al. GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells , 2007, FEBS letters.
[159] Jianren Gu,et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity , 2007, International journal of cancer.
[160] D. Häussinger,et al. CD133+ hepatic stellate cells are progenitor cells. , 2007, Biochemical and biophysical research communications.
[161] L. Ricci-Vitiani,et al. Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.
[162] J. Dick,et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.
[163] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[164] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[165] W. Huttner,et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells , 2005, Journal of Cell Science.
[166] W. Sadee,et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.
[167] S. Rafii,et al. AC133/CD133/Prominin-1. , 2005, The international journal of biochemistry & cell biology.
[168] K. Boheler,et al. Somatic Stem Cell Marker Prominin‐1/CD133 Is Expressed in Embryonic Stem Cell–Derived Progenitors , 2005, Stem cells.
[169] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[170] W. Huttner,et al. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis , 2004, Journal of Cell Science.
[171] C. Robson,et al. CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.
[172] Giulio Cossu,et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. , 2004, The Journal of clinical investigation.
[173] D. Ribatti. The involvement of endothelial progenitor cells in tumor angiogenesis , 2004, Journal of cellular and molecular medicine.
[174] S. Rafii,et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. , 2004, Blood.
[175] Cynthia Hawkins,et al. Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.
[176] W. Huttner,et al. Characterization of Prominin-2, a New Member of the Prominin Family of Pentaspan Membrane Glycoproteins* 210 , 2003, The Journal of Biological Chemistry.
[177] H. Frank,et al. Monoclonal Antibody CD133–2 (AC141) Against Hematopoietic Stem Cell Antigen CD133 Shows Crossreactivity with Cytokeratin 18 , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[178] I. Weissman,et al. Direct isolation of human central nervous system stem cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[179] W. Huttner,et al. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane , 2000, Nature Cell Biology.
[180] W. Huttner,et al. The Human AC133 Hematopoietic Stem Cell Antigen Is also Expressed in Epithelial Cells and Targeted to Plasma Membrane Protrusions* , 2000, The Journal of Biological Chemistry.
[181] S. Rafii,et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.
[182] J. Kearney,et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.
[183] R. Warnke,et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. , 1997, Blood.
[184] W. Huttner,et al. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[185] OUP accepted manuscript , 2022, Stem Cells.
[186] M. Bandehpour,et al. An In-silico Approach and Experimental Analysis Combination: Two Strategies for Selecting the third Extracellular Domain (D-EC3) of Human CD133 Marker as a Target for Detection of Cancer Stem Cells , 2021, Iranian journal of pharmaceutical research : IJPR.
[187] M. Pocard,et al. CD133 Clinical Trials: Safety and Efficacy , 2019 .
[188] W. Fang,et al. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. , 2018, International journal of clinical and experimental pathology.
[189] Bin Huang,et al. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis , 2014, Molecular Neurobiology.
[190] N. Maitland,et al. Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells. , 2013, Advances in experimental medicine and biology.
[191] Yi-Wei Chen,et al. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. , 2013, Oral oncology.
[192] L. Ricci-Vitiani,et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis , 2011, Cancer.
[193] M. Raffeld,et al. Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. , 2010, Methods in molecular biology.
[194] S. Raghavendra,et al. Xylene: An overview of its health hazards and preventive measures , 2010, Journal of oral and maxillofacial pathology : JOMFP.
[195] I. Bayazitov,et al. A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.
[196] W. Huttner,et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer , 2004, Cell and Tissue Research.
[197] W. Huttner,et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. , 2000, Human molecular genetics.